1-12 of 12
Jennifer R. Diamond
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew J. Brenner, Alison Stopeck, Hannah Parris, Dexiang Gao, Tessa McSpadden, Jose Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5021–5030.
https://doi.org/10.1158/1078-0432.CCR-23-0117
Published: 15 December 2023
View article titled, Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Open the PDF for Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2969.
https://doi.org/10.1158/1078-0432.CCR-22-1792
Published: 01 July 2022
View article titled, Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Journal Articles

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Jennifer R. Diamond, Valentina Boni, Emerson Lim, Grzegorz Nowakowski, Raul Cordoba, Daniel Morillo, Ray Valencia, Isabelle Genvresse, Claudia Merz, Oliver Boix, Melanie M. Frigault, Joy M. Greer, Ahmed M. Hamdy, Xin Huang, Raquel Izumi, Harvey Wong, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1285–1293.
https://doi.org/10.1158/1078-0432.CCR-21-3617
Published: 01 April 2022
View article titled, First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Open the PDF for First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6366–6375.
https://doi.org/10.1158/1078-0432.CCR-20-4185
Published: 01 December 2021
View article titled, A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Includes: Supplementary data
Journal Articles

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3329–3338.
https://doi.org/10.1158/1078-0432.CCR-20-4131
Published: 15 June 2021
View article titled, Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Open the PDF for Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4633–4642.
https://doi.org/10.1158/1078-0432.CCR-19-3498
Published: 01 September 2020
View article titled, Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Open the PDF for Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4

Priscilla K. Stumpf, Diana M. Cittelly, Tyler P. Robin, Julie A. Carlson, Kelly A. Stuhr, Maria Jose Contreras-Zarate, Steven Lai, D. Ryan Ormond, Chad G. Rusthoven, Laurie E. Gaspar, Rachel Rabinovitch, Brian D. Kavanagh, Arthur Liu, Jennifer R. Diamond, Peter Kabos, Christine M. Fisher
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3946–3953.
https://doi.org/10.1158/1078-0432.CCR-18-2851
Published: 01 July 2019
View article titled, Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4
Open the PDF for Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4 in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, Jennifer R. Diamond, Anne Younger, Wells A. Messersmith, Lieve Adriaens, Liming Liu, Richard J. Kao, Albert Thomas DiCioccio, Ana Kostic, Russell Leek, Adrian Harris, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2695–2703.
https://doi.org/10.1158/1078-0432.CCR-14-2797
Published: 14 June 2015
View article titled, A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Open the PDF for A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler, Stephen B. Keysar, Elizabeth Freas, Dara L. Aisner, Chen Ren, Aik-Chook Tan, Francois Wilhelm, Manoj Maniar, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1656–1665.
https://doi.org/10.1158/1078-0432.CCR-13-2506
Published: 13 March 2014
View article titled, Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varella-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 291–303.
https://doi.org/10.1158/1078-0432.CCR-12-1611
Published: 02 January 2013
View article titled, Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models

John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 2989–2998.
https://doi.org/10.1158/1078-0432.CCR-10-0325
Published: 31 May 2010
View article titled, Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
Open the PDF for Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models in another window